欧米医薬品製造市場の規模、シェア、動向分析レポート 製品タイプ別、タイプ別、医薬品開発タイプ別、製剤別、投与経路別、セグメント別予測、2023年~2030年U.S. And Europe Pharmaceutical Manufacturing Market Size, Share & Trends Analysis Report By Product Type, By Type, By Drug Development Type, By Formulation, By Routes of Administration, And Segment Forecasts, 2023 - 2030 米国・欧州医薬品製造市場の成長とトレンド Grand View Research, Inc.の新しいレポートによると、米国と欧州の医薬品製造市場規模は2030年までに6412億2000万米ドルに達し、2023年から2030年まで6.81%のCAGR... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリー米国・欧州医薬品製造市場の成長とトレンドGrand View Research, Inc.の新しいレポートによると、米国と欧州の医薬品製造市場規模は2030年までに6412億2000万米ドルに達し、2023年から2030年まで6.81%のCAGRで拡大すると予測されています。支持的な規制法の存在、特許性規範、製薬業界への高い投資、医療費の増加は、依然として成長の主要な推進要因となっています。また、製薬業界における第三者生産の傾向の高まりや、コスト削減への取り組みの重視は、有利な成長機会をもたらすと考えられます。 医薬品の臨床試験件数の継続的な増加は、今後数年間、市場成長のための数多くの機会を生み出すと期待されています。ClinicalTrials.govによると、2023年1月現在、米国では合計137,145件の進行中の臨床試験が登録されており、これは臨床試験全体の31%を占めている。このような臨床試験数の増加は、製薬業界の成長を示しており、市場関係者に新たな道を切り開くものと思われます。 さらに、医薬品メーカーの大半は、医薬品不足を克服し、製造コストを削減し、製造効率を向上させるために、連続生産方式を選択するようになりました。例えば、2021年1月、CONTINUUS Pharmaceuticals Inc.は、重症患者を治療するための3つの必須医薬品の国レベルでの生産を加速させるための6930万米ドルの米国政府契約の受領を発表しました。さらに、この契約により、同社はコスト効率の高い生産を可能にし、高品質で手頃な価格の治療薬を患者に提供することを促進しました。 国内の医薬品製造拠点を設立するための政府のイニシアチブは、医薬品製造市場の成長を決定する要因の1つです。例えば、2022年4月、CureVacとGSK plcは、mRNAの生産能力を高めるためにドイツのパンデミック危機管理計画の一部となるパートナーシップを締結し、政府は2029年までCureVacの生産能力へのアクセスを受けることになります。 英国政府は、Medicines Manufacturing Innovation Centreを通じて、現地生産の確立に向けた取り組みを進めています。このプログラムでは、医薬品メーカー、学術機関、医療提供者、規制機関が、この施設でそれぞれのリソースを結集し、自律的な生産を含む新しい技術のテストと強化を行うことが期待されています。 さらに、製薬会社が事業の道筋を強化するために行う有機的・無機的な開発は、市場の拡大をサポートすると予想されます。例えば、2021年10月、Samsung BiologicsとEnzolytics, Inc.は、抗SARS-CoV-2モノクローナル抗体と抗HIV療法の開発&製造契約を締結した。同様に、2021年2月、WuXi STAはスイスにあるBristol Myers Squibbの製造部門を買収しました。この拡張により、既存の能力がさらに強化されます。 米国および欧州の医薬品製造市場ハイライト - 低分子の消費率の高さと製品認可の増加により、2022年に低分子分野が最大のシェアを占める - 低投資や高い製造効率など、アウトソース製造に伴う様々な利点により、2022年にアウトソース部門が最大の市場シェアを占めた - 剤形別では、2022年に錠剤が米国・欧州の医薬品製造業界を支配し、スプレー分野が急成長すると予想される - 売れ筋の製剤が経口剤として入手しやすく、経口製剤の需要が高いことから、2022年に経口分野が最大となった - 治療領域別では、がん分野が最大の収益シェアを占めています。一方、呼吸器疾患分野は飛躍的な成長が見込まれています。 - 欧州は、良好な政府政策と継続的な研究活動により、予測期間中に最も速い成長を示すと予想される 目次Table of ContentsChapter 1 Methodology and Scope 1.1 Market Segmentation and Scope 1.1.1 Segment scope 1.1.2 Regional scope 1.1.3 Estimates and forecast timeline 1.2 Research Methodology 1.3 Information Procurement 1.3.1 Purchased database 1.3.2 GVR’s internal database 1.3.3 Secondary sources 1.3.4 Primary research 1.3.5 Details of primary research 1.4 Information or Data Analysis 1.4.1 Data analysis models 1.5 Market Formulation & Validation 1.6 Model Details 1.6.1 Commodity Flow Analysis 1.6.1.1 Approach: Commodity Flow Approach 1.7 Research Assumptions 1.8 List of Secondary Sources 1.9 List of Abbreviations 1.10 Objectives 1.10.1 Objective 1 1.10.2 Objective 2 1.10.3 Objective 3 1.10.4 Objective 4 Chapter 2 Executive Summary 2.1 Market Outlook 2.2 Competitive Insights Chapter 3 U.S. & Europe Pharmaceutical Manufacturing Market Variables, Trends, & Scope 3.1 Market Lineage Outlook 3.1.1 Parent market 3.2 Market Dynamics 3.2.1 Market drivers analysis 3.2.1.1 Rise in pharmaceutical R&D spending 3.2.1.2 Advancements in pharmaceutical manufacturing technologies 3.2.1.3 Increasing geriatric population and incidence of chronic disorders 3.2.2 Market restraint analysis 3.2.2.1 Challenges pertaining to pharma supply chain 3.2.2.2 Pricing pressures on pharmaceutical companies 3.3 Penetration & Growth Prospect Mapping 3.4 U.S. & Europe Pharmaceutical Manufacturing Market: Market Analysis Tools 3.4.1 Industry analysis - Porter’s 3.4.2 PESTLE analysis 3.5 Regulatory Framework 3.6 Pricing Analysis Chapter 4 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Product Type, 2018 - 2030 (USD Billion) 4.1 Definition and Scope 4.2 Product Type Market Share Analysis, 2022 & 2030 4.3 Segment Dashboard 4.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Product Type, 2018 to 2030 4.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030 4.5.1 Small Molecule 4.5.1.1 Small molecule market estimates and forecast, 2018 - 2030 (USD Billion) 4.5.2 Large Molecule 4.5.2.1 Large molecule market estimates and forecast, 2018 - 2030 (USD Billion) 4.5.2.1.1 Monoclonal Antibodies 4.5.2.1.1.1 Monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion) 4.5.2.1.2 Vaccines 4.5.2.1.2.1 Vaccines market estimates and forecast, 2018 - 2030 (USD Billion) 4.5.2.1.3 Cell & Gene Therapy 4.5.2.1.3.1 Cell & Gene therapy market estimates and forecast, 2018 - 2030 (USD Billion) 4.5.2.1.4 Others 4.5.2.1.4.1 Others molecule market estimates and forecast, 2018 - 2030 (USD Billion) Chapter 5 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Drug Development Type 2018 - 2030 (USD Billion) 5.1 Definition and Scope 5.2 Drug Development Type Market Share Analysis, 2022 & 2030 5.3 Segment Dashboard 5.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Drug Development Type, 2018 to 2030 5.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030 5.5.1 Outsource 5.5.1.1 Outsource market estimates and forecast, 2018 - 2030 (USD Billion) 5.5.2 In - house 5.5.2.1 In - house market estimates and forecast, 2018 - 2030 (USD Billion) Chapter 6 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Route of Administration, 2018 - 2030 (USD Billion) 6.1 Definition and Scope 6.2 Route of Administration Market Share Analysis, 2022 & 2030 6.3 Segment Dashboard 6.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Route of Administration, 2018 to 2030 6.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030 6.5.1 Oral 6.5.1.1 Oral market estimates and forecast, 2018 - 2030 (USD Billion) 6.5.2 Topical 6.5.2.1 Topical market estimates and forecast, 2018 - 2030 (USD Billion) 6.5.3 Parenterals 6.5.3.1 Parenterals market estimates and forecast, 2018 - 2030 (USD Billion) 6.5.4 Inhalations 6.5.4.1 Inhalations market estimates and forecast, 2018 - 2030 (USD Billion) 6.5.5 Others 6.5.5.1 Others market estimates and forecast, 2018 - 2030 (USD Billion) Chapter 7 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Formulation, 2018 - 2030 (USD Billion) 7.1 Definition and Scope 7.2 Formulation Market Share Analysis, 2022 & 2030 7.3 Segment Dashboard 7.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Formulation, 2018 to 2030 7.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030 7.5.1 Tablets 7.5.1.1 Tablets market estimates and forecast, 2018 - 2030 (USD Billion) 7.5.2 Capsules 7.5.2.1 Capsules market estimates and forecast, 2018 - 2030 (USD Billion) 7.5.3 Injectables 7.5.3.1 Injectables market estimates and forecast, 2018 - 2030 (USD Billion) 7.5.4 Sprays 7.5.4.1 Sprays market estimates and forecast, 2018 - 2030 (USD Billion) 7.5.5 Suspensions 7.5.5.1 Suspensions market estimates and forecast, 2018 - 2030 (USD Billion) 7.5.6 Powders 7.5.6.1 Powders market estimates and forecast, 2018 - 2030 (USD Billion) 7.5.7 Others 7.5.7.1 Others market estimates and forecast, 2018 - 2030 (USD Billion) Chapter 8 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Therapy Area, 2018 - 2030 (USD Billion) 8.1 Definition and Scope 8.2 Therapy Area Market Share Analysis, 2022 & 2030 8.3 Segment Dashboard 8.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Therapy Area, 2018 to 2030 8.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030 8.5.1 Cardiovascular Diseases 8.5.1.1 Cardiovascular diseases market estimates and forecast, 2018 - 2030 (USD Billion) 8.5.2 Pain 8.5.2.1 Pain market estimates and forecast, 2018 - 2030 (USD Billion) 8.5.3 Diabetes 8.5.3.1 Diabetes market estimates and forecast, 2018 - 2030 (USD Billion) 8.5.4 Cancer 8.5.4.1 Cancer market estimates and forecast, 2018 - 2030 (USD Billion) 8.5.5 Respiratory Diseases 8.5.5.1 Respiratory diseases market estimates and forecast, 2018 - 2030 (USD Billion) 8.5.6 Others 8.5.6.1 Others market estimates and forecast, 2018 - 2030 (USD Billion) Chapter 9 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Prescription Requirements, 2018 - 2030 (USD Billion) 9.1 Definition and Scope 9.2 Prescription Requirements Market Share Analysis, 2022 & 2030 9.3 Segment Dashboard 9.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Prescription Requirements, 2018 to 2030 9.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030 9.5.1 Prescription Medicines 9.5.1.1 Prescription medicines market estimates and forecast, 2018 - 2030 (USD Billion) 9.5.2 Over - the - counter (OTC) Medicines 9.5.2.1 Over - the - counter (OTC) medicines market estimates and forecast, 2018 - 2030 (USD Billion) Chapter 10 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Age Type, 2018 - 2030 (USD Billion) 10.1 Definition and Scope 10.2 Age Type Market Share Analysis, 2022 & 2030 10.3 Segment Dashboard 10.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Age Type, 2018 to 2030 10.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030 10.5.1 Children & Adolescents 10.5.1.1 Children & adolescents market estimates and forecast, 2018 - 2030 (USD Billion) 10.5.2 Adults 10.5.2.1 Adults market estimates and forecast, 2018 - 2030 (USD Billion) 10.5.3 Geriatric 10.5.3.1 Geriatric market estimates and forecast, 2018 - 2030 (USD Billion) Chapter 11 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Sales Channel, 2018 - 2030 (USD Billion) 11.1 Definition and Scope 11.2 Sales Channel Market Share Analysis, 2022 & 2030 11.3 Segment Dashboard 11.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Sales Channel, 2018 to 2030 11.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030 11.5.1 Retail 11.5.1.1 Retail market estimates and forecast, 2018 - 2030 (USD Billion) 11.5.2 Non - retail 11.5.2.1 Non - retail market estimates and forecast, 2018 - 2030 (USD Billion) Chapter 12 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Region, 2018 - 2030 (USD Billion) 12.1 Definition & Scope 12.2 Regional Market Share Analysis, 2022 & 2030 12.3 Regional Market Dashboard 12.4 Regional Market Snapshot 12.5 SWOT Analysis 12.5.1 U.S. 12.5.2 Europe 12.6 Market Size, & Forecasts, Revenue and Trend Analysis, 2022 to 2030 12.6.1 U.S. 12.6.1.1 Key Country Dynamics 12.6.1.2 Competitive Scenario 12.6.1.3 Regulatory Framework 12.6.1.4 Reimbursement Scenario 12.6.1.5 U.S. market estimates and forecast, 2018 - 2030 (USD Billion) 12.6.2 Europe 12.6.2.1 Europe pharmaceutical manufacturing market, 2018 - 2030 (USD Billion) 12.6.2.2 U.K. 12.6.2.2.1 Key Country Dynamics 12.6.2.2.2 Competitive Scenario 12.6.2.2.3 Regulatory Framework 12.6.2.2.4 Reimbursement Scenario 12.6.2.2.5 U.K. pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion) 12.6.2.3 Germany 12.6.2.3.1 Key Country Dynamics 12.6.2.3.2 Competitive Scenario 12.6.2.3.3 Regulatory Framework 12.6.2.3.4 Reimbursement Scenario 12.6.2.3.5 Germany pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion) 12.6.2.4 Spain 12.6.2.4.1 Key Country Dynamics 12.6.2.4.2 Competitive Scenario 12.6.2.4.3 Regulatory Framework 12.6.2.4.4 Reimbursement Scenario 12.6.2.4.5 Spain pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion) 12.6.2.5 France 12.6.2.5.1 Key Country Dynamics 12.6.2.5.2 Competitive Scenario 12.6.2.5.3 Regulatory Framework 12.6.2.5.4 Reimbursement Scenario 12.6.2.5.5 France pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion) 12.6.2.6 Italy 12.6.2.6.1 Key Country Dynamics 12.6.2.6.2 Competitive Scenario 12.6.2.6.3 Regulatory Framework 12.6.2.6.4 Reimbursement Scenario 12.6.2.6.5 Italy pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion) 12.6.2.7 Denmark 12.6.2.7.1 Key Country Dynamics 12.6.2.7.2 Competitive Scenario 12.6.2.7.3 Regulatory Framework 12.6.2.7.4 Reimbursement Scenario 12.6.2.7.5 Denmark pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion) 12.6.2.8 Sweden 12.6.2.8.1 Key Country Dynamics 12.6.2.8.2 Competitive Scenario 12.6.2.8.3 Regulatory Framework 12.6.2.8.4 Reimbursement Scenario 12.6.2.8.5 Sweden pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion) 12.6.2.9 Norway 12.6.2.9.1 Key Country Dynamics 12.6.2.9.2 Competitive Scenario 12.6.2.9.3 Regulatory Framework 12.6.2.9.4 Reimbursement Scenario 12.6.2.9.5 Norway pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion) Chapter 13 U.S. & Europe Pharmaceutical Manufacturing Market - Competitive Analysis 13.1 Recent Developments & Impact Analysis, by Key Market Participants 13.1.1 Ansoff matrix 13.1.2 Heat map analysis 13.1.3 Major Deals and Strategic Alliances Analysis 13.1.3.1 Joint Ventures 13.1.3.2 Licensing Agreements 13.1.3.3 Product Launches 13.1.3.4 Conferences and Campaigns 13.2 Company Categorization 13.2.1 Innovators 13.2.2 Market Leaders 13.3 Vendor Landscape 13.3.1 List of key distributors and channel partners 13.3.2 Key customers 13.4 Public Companies 13.4.1 Competitive Dashboard Analysis 13.4.1.1 Market Differentiators 13.5 Private Companies 13.5.1 List of key emerging companies 13.6 Company Profiles 13.6.1 AbbVie Inc 13.6.1.1 Company overview 13.6.1.2 Financial performance 13.6.1.3 Product benchmarking 13.6.1.4 Strategic Initiatives 13.6.2 Pfizer Inc. 13.6.2.1 Company overview 13.6.2.2 Financial performance 13.6.2.3 Product benchmarking 13.6.2.4 Strategic Initiatives 13.6.3 Novartis AG 13.6.3.1 Company overview 13.6.3.2 Financial performance 13.6.3.3 Product benchmarking 13.6.3.4 Strategic Initiatives 13.6.4 F. Hoffmann - La Roche Ltd 13.6.4.1 Company overview 13.6.4.2 Financial performance 13.6.4.3 Product benchmarking 13.6.4.4 Strategic Initiatives 13.6.5 Merck & Co., Inc. 13.6.5.1 Company overview 13.6.5.2 Financial performance 13.6.5.3 Product benchmarking 13.6.5.4 Strategic Initiatives 13.6.6 Johnson & Johnson Services, Inc. 13.6.6.1 Company overview 13.6.6.2 Financial performance 13.6.6.3 Product benchmarking 13.6.6.4 Strategic Initiatives 13.6.7 GSK plc 13.6.7.1 Company overview 13.6.7.2 Financial performance 13.6.7.3 Product benchmarking 13.6.7.4 Strategic initiatives 13.6.8 Sanofi 13.6.8.1 Company overview 13.6.8.2 Financial performance 13.6.8.3 Product benchmarking 13.6.8.4 Strategic initiatives 13.6.9 Lonza 13.6.9.1 Company overview 13.6.9.2 Financial performance 13.6.9.3 Product benchmarking 13.6.9.4 Strategic initiatives 13.6.10 Samsung Biologics 13.6.10.1 Company overview 13.6.10.2 Financial performance 13.6.10.3 Product benchmarking 13.6.10.4 Strategic initiatives 13.6.11 Lilly 13.6.11.1 Company overview 13.6.11.2 Financial performance 13.6.11.3 Product benchmarking 13.6.11.4 Strategic initiatives
SummaryU.S. And Europe Pharmaceutical Manufacturing Market Growth & Trends Table of ContentsTable of ContentsChapter 1 Methodology and Scope 1.1 Market Segmentation and Scope 1.1.1 Segment scope 1.1.2 Regional scope 1.1.3 Estimates and forecast timeline 1.2 Research Methodology 1.3 Information Procurement 1.3.1 Purchased database 1.3.2 GVR’s internal database 1.3.3 Secondary sources 1.3.4 Primary research 1.3.5 Details of primary research 1.4 Information or Data Analysis 1.4.1 Data analysis models 1.5 Market Formulation & Validation 1.6 Model Details 1.6.1 Commodity Flow Analysis 1.6.1.1 Approach: Commodity Flow Approach 1.7 Research Assumptions 1.8 List of Secondary Sources 1.9 List of Abbreviations 1.10 Objectives 1.10.1 Objective 1 1.10.2 Objective 2 1.10.3 Objective 3 1.10.4 Objective 4 Chapter 2 Executive Summary 2.1 Market Outlook 2.2 Competitive Insights Chapter 3 U.S. & Europe Pharmaceutical Manufacturing Market Variables, Trends, & Scope 3.1 Market Lineage Outlook 3.1.1 Parent market 3.2 Market Dynamics 3.2.1 Market drivers analysis 3.2.1.1 Rise in pharmaceutical R&D spending 3.2.1.2 Advancements in pharmaceutical manufacturing technologies 3.2.1.3 Increasing geriatric population and incidence of chronic disorders 3.2.2 Market restraint analysis 3.2.2.1 Challenges pertaining to pharma supply chain 3.2.2.2 Pricing pressures on pharmaceutical companies 3.3 Penetration & Growth Prospect Mapping 3.4 U.S. & Europe Pharmaceutical Manufacturing Market: Market Analysis Tools 3.4.1 Industry analysis - Porter’s 3.4.2 PESTLE analysis 3.5 Regulatory Framework 3.6 Pricing Analysis Chapter 4 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Product Type, 2018 - 2030 (USD Billion) 4.1 Definition and Scope 4.2 Product Type Market Share Analysis, 2022 & 2030 4.3 Segment Dashboard 4.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Product Type, 2018 to 2030 4.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030 4.5.1 Small Molecule 4.5.1.1 Small molecule market estimates and forecast, 2018 - 2030 (USD Billion) 4.5.2 Large Molecule 4.5.2.1 Large molecule market estimates and forecast, 2018 - 2030 (USD Billion) 4.5.2.1.1 Monoclonal Antibodies 4.5.2.1.1.1 Monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion) 4.5.2.1.2 Vaccines 4.5.2.1.2.1 Vaccines market estimates and forecast, 2018 - 2030 (USD Billion) 4.5.2.1.3 Cell & Gene Therapy 4.5.2.1.3.1 Cell & Gene therapy market estimates and forecast, 2018 - 2030 (USD Billion) 4.5.2.1.4 Others 4.5.2.1.4.1 Others molecule market estimates and forecast, 2018 - 2030 (USD Billion) Chapter 5 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Drug Development Type 2018 - 2030 (USD Billion) 5.1 Definition and Scope 5.2 Drug Development Type Market Share Analysis, 2022 & 2030 5.3 Segment Dashboard 5.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Drug Development Type, 2018 to 2030 5.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030 5.5.1 Outsource 5.5.1.1 Outsource market estimates and forecast, 2018 - 2030 (USD Billion) 5.5.2 In - house 5.5.2.1 In - house market estimates and forecast, 2018 - 2030 (USD Billion) Chapter 6 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Route of Administration, 2018 - 2030 (USD Billion) 6.1 Definition and Scope 6.2 Route of Administration Market Share Analysis, 2022 & 2030 6.3 Segment Dashboard 6.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Route of Administration, 2018 to 2030 6.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030 6.5.1 Oral 6.5.1.1 Oral market estimates and forecast, 2018 - 2030 (USD Billion) 6.5.2 Topical 6.5.2.1 Topical market estimates and forecast, 2018 - 2030 (USD Billion) 6.5.3 Parenterals 6.5.3.1 Parenterals market estimates and forecast, 2018 - 2030 (USD Billion) 6.5.4 Inhalations 6.5.4.1 Inhalations market estimates and forecast, 2018 - 2030 (USD Billion) 6.5.5 Others 6.5.5.1 Others market estimates and forecast, 2018 - 2030 (USD Billion) Chapter 7 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Formulation, 2018 - 2030 (USD Billion) 7.1 Definition and Scope 7.2 Formulation Market Share Analysis, 2022 & 2030 7.3 Segment Dashboard 7.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Formulation, 2018 to 2030 7.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030 7.5.1 Tablets 7.5.1.1 Tablets market estimates and forecast, 2018 - 2030 (USD Billion) 7.5.2 Capsules 7.5.2.1 Capsules market estimates and forecast, 2018 - 2030 (USD Billion) 7.5.3 Injectables 7.5.3.1 Injectables market estimates and forecast, 2018 - 2030 (USD Billion) 7.5.4 Sprays 7.5.4.1 Sprays market estimates and forecast, 2018 - 2030 (USD Billion) 7.5.5 Suspensions 7.5.5.1 Suspensions market estimates and forecast, 2018 - 2030 (USD Billion) 7.5.6 Powders 7.5.6.1 Powders market estimates and forecast, 2018 - 2030 (USD Billion) 7.5.7 Others 7.5.7.1 Others market estimates and forecast, 2018 - 2030 (USD Billion) Chapter 8 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Therapy Area, 2018 - 2030 (USD Billion) 8.1 Definition and Scope 8.2 Therapy Area Market Share Analysis, 2022 & 2030 8.3 Segment Dashboard 8.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Therapy Area, 2018 to 2030 8.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030 8.5.1 Cardiovascular Diseases 8.5.1.1 Cardiovascular diseases market estimates and forecast, 2018 - 2030 (USD Billion) 8.5.2 Pain 8.5.2.1 Pain market estimates and forecast, 2018 - 2030 (USD Billion) 8.5.3 Diabetes 8.5.3.1 Diabetes market estimates and forecast, 2018 - 2030 (USD Billion) 8.5.4 Cancer 8.5.4.1 Cancer market estimates and forecast, 2018 - 2030 (USD Billion) 8.5.5 Respiratory Diseases 8.5.5.1 Respiratory diseases market estimates and forecast, 2018 - 2030 (USD Billion) 8.5.6 Others 8.5.6.1 Others market estimates and forecast, 2018 - 2030 (USD Billion) Chapter 9 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Prescription Requirements, 2018 - 2030 (USD Billion) 9.1 Definition and Scope 9.2 Prescription Requirements Market Share Analysis, 2022 & 2030 9.3 Segment Dashboard 9.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Prescription Requirements, 2018 to 2030 9.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030 9.5.1 Prescription Medicines 9.5.1.1 Prescription medicines market estimates and forecast, 2018 - 2030 (USD Billion) 9.5.2 Over - the - counter (OTC) Medicines 9.5.2.1 Over - the - counter (OTC) medicines market estimates and forecast, 2018 - 2030 (USD Billion) Chapter 10 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Age Type, 2018 - 2030 (USD Billion) 10.1 Definition and Scope 10.2 Age Type Market Share Analysis, 2022 & 2030 10.3 Segment Dashboard 10.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Age Type, 2018 to 2030 10.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030 10.5.1 Children & Adolescents 10.5.1.1 Children & adolescents market estimates and forecast, 2018 - 2030 (USD Billion) 10.5.2 Adults 10.5.2.1 Adults market estimates and forecast, 2018 - 2030 (USD Billion) 10.5.3 Geriatric 10.5.3.1 Geriatric market estimates and forecast, 2018 - 2030 (USD Billion) Chapter 11 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Sales Channel, 2018 - 2030 (USD Billion) 11.1 Definition and Scope 11.2 Sales Channel Market Share Analysis, 2022 & 2030 11.3 Segment Dashboard 11.4 U.S. & Europe Pharmaceutical Manufacturing Market, by Sales Channel, 2018 to 2030 11.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030 11.5.1 Retail 11.5.1.1 Retail market estimates and forecast, 2018 - 2030 (USD Billion) 11.5.2 Non - retail 11.5.2.1 Non - retail market estimates and forecast, 2018 - 2030 (USD Billion) Chapter 12 U.S. & Europe Pharmaceutical Manufacturing Market Segment Analysis, By Region, 2018 - 2030 (USD Billion) 12.1 Definition & Scope 12.2 Regional Market Share Analysis, 2022 & 2030 12.3 Regional Market Dashboard 12.4 Regional Market Snapshot 12.5 SWOT Analysis 12.5.1 U.S. 12.5.2 Europe 12.6 Market Size, & Forecasts, Revenue and Trend Analysis, 2022 to 2030 12.6.1 U.S. 12.6.1.1 Key Country Dynamics 12.6.1.2 Competitive Scenario 12.6.1.3 Regulatory Framework 12.6.1.4 Reimbursement Scenario 12.6.1.5 U.S. market estimates and forecast, 2018 - 2030 (USD Billion) 12.6.2 Europe 12.6.2.1 Europe pharmaceutical manufacturing market, 2018 - 2030 (USD Billion) 12.6.2.2 U.K. 12.6.2.2.1 Key Country Dynamics 12.6.2.2.2 Competitive Scenario 12.6.2.2.3 Regulatory Framework 12.6.2.2.4 Reimbursement Scenario 12.6.2.2.5 U.K. pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion) 12.6.2.3 Germany 12.6.2.3.1 Key Country Dynamics 12.6.2.3.2 Competitive Scenario 12.6.2.3.3 Regulatory Framework 12.6.2.3.4 Reimbursement Scenario 12.6.2.3.5 Germany pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion) 12.6.2.4 Spain 12.6.2.4.1 Key Country Dynamics 12.6.2.4.2 Competitive Scenario 12.6.2.4.3 Regulatory Framework 12.6.2.4.4 Reimbursement Scenario 12.6.2.4.5 Spain pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion) 12.6.2.5 France 12.6.2.5.1 Key Country Dynamics 12.6.2.5.2 Competitive Scenario 12.6.2.5.3 Regulatory Framework 12.6.2.5.4 Reimbursement Scenario 12.6.2.5.5 France pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion) 12.6.2.6 Italy 12.6.2.6.1 Key Country Dynamics 12.6.2.6.2 Competitive Scenario 12.6.2.6.3 Regulatory Framework 12.6.2.6.4 Reimbursement Scenario 12.6.2.6.5 Italy pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion) 12.6.2.7 Denmark 12.6.2.7.1 Key Country Dynamics 12.6.2.7.2 Competitive Scenario 12.6.2.7.3 Regulatory Framework 12.6.2.7.4 Reimbursement Scenario 12.6.2.7.5 Denmark pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion) 12.6.2.8 Sweden 12.6.2.8.1 Key Country Dynamics 12.6.2.8.2 Competitive Scenario 12.6.2.8.3 Regulatory Framework 12.6.2.8.4 Reimbursement Scenario 12.6.2.8.5 Sweden pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion) 12.6.2.9 Norway 12.6.2.9.1 Key Country Dynamics 12.6.2.9.2 Competitive Scenario 12.6.2.9.3 Regulatory Framework 12.6.2.9.4 Reimbursement Scenario 12.6.2.9.5 Norway pharmaceutical manufacturing market estimates and forecast, 2018 - 2030 (USD Billion) Chapter 13 U.S. & Europe Pharmaceutical Manufacturing Market - Competitive Analysis 13.1 Recent Developments & Impact Analysis, by Key Market Participants 13.1.1 Ansoff matrix 13.1.2 Heat map analysis 13.1.3 Major Deals and Strategic Alliances Analysis 13.1.3.1 Joint Ventures 13.1.3.2 Licensing Agreements 13.1.3.3 Product Launches 13.1.3.4 Conferences and Campaigns 13.2 Company Categorization 13.2.1 Innovators 13.2.2 Market Leaders 13.3 Vendor Landscape 13.3.1 List of key distributors and channel partners 13.3.2 Key customers 13.4 Public Companies 13.4.1 Competitive Dashboard Analysis 13.4.1.1 Market Differentiators 13.5 Private Companies 13.5.1 List of key emerging companies 13.6 Company Profiles 13.6.1 AbbVie Inc 13.6.1.1 Company overview 13.6.1.2 Financial performance 13.6.1.3 Product benchmarking 13.6.1.4 Strategic Initiatives 13.6.2 Pfizer Inc. 13.6.2.1 Company overview 13.6.2.2 Financial performance 13.6.2.3 Product benchmarking 13.6.2.4 Strategic Initiatives 13.6.3 Novartis AG 13.6.3.1 Company overview 13.6.3.2 Financial performance 13.6.3.3 Product benchmarking 13.6.3.4 Strategic Initiatives 13.6.4 F. Hoffmann - La Roche Ltd 13.6.4.1 Company overview 13.6.4.2 Financial performance 13.6.4.3 Product benchmarking 13.6.4.4 Strategic Initiatives 13.6.5 Merck & Co., Inc. 13.6.5.1 Company overview 13.6.5.2 Financial performance 13.6.5.3 Product benchmarking 13.6.5.4 Strategic Initiatives 13.6.6 Johnson & Johnson Services, Inc. 13.6.6.1 Company overview 13.6.6.2 Financial performance 13.6.6.3 Product benchmarking 13.6.6.4 Strategic Initiatives 13.6.7 GSK plc 13.6.7.1 Company overview 13.6.7.2 Financial performance 13.6.7.3 Product benchmarking 13.6.7.4 Strategic initiatives 13.6.8 Sanofi 13.6.8.1 Company overview 13.6.8.2 Financial performance 13.6.8.3 Product benchmarking 13.6.8.4 Strategic initiatives 13.6.9 Lonza 13.6.9.1 Company overview 13.6.9.2 Financial performance 13.6.9.3 Product benchmarking 13.6.9.4 Strategic initiatives 13.6.10 Samsung Biologics 13.6.10.1 Company overview 13.6.10.2 Financial performance 13.6.10.3 Product benchmarking 13.6.10.4 Strategic initiatives 13.6.11 Lilly 13.6.11.1 Company overview 13.6.11.2 Financial performance 13.6.11.3 Product benchmarking 13.6.11.4 Strategic initiatives
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医薬)の最新刊レポート
Grand View Research社の医薬品分野での最新刊レポート
本レポートと同じKEY WORD()の最新刊レポート
よくあるご質問Grand View Research社はどのような調査会社ですか?グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/15 10:26 157.84 円 166.62 円 202.61 円 |